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Abstract: Sulodexide is a highly purified glycosaminoglycan containing a combination 
of heparan sulfate with affinity for antithrombin III and dermatan sulfate with affinity for 
heparin cofactor II. This antithrombotic and antithrombin activity is of great pharmacologic 
interest and makes sulodexide a suitable drug for the prophylaxis and treatment of arterial 
and  venous  peripheral  diseases.  In  arterial  pathology,  changes  in  the  Winsor  Index, 
improvement in peripheral blood flow, and reduction in pain-free walking distance confirm 
that treatment with oral sulodexide is effective. Lipid components linked to the genesis 
of peripheral vascular processes, including triglycerides, total cholesterol, and low-density 
lipoprotein fractions, as well as plasma and blood viscosity, are reduced by the administration 
of sulodexide, whereas the high-density lipoprotein fraction increases. Sulodexide inhibits 
aggregation and adhesion of platelets at the level of the vascular wall, reduces plasma 
fibrinogen concentrations, reduces plasminogen activator inhibitor-1, and increases tissue 
plasminogen activator, as well as systemic fibrinolytic and thrombolytic activity, thereby 
demonstrating efficacy in the treatment of thromboembolic disease. There is no interaction 
between sulodexide and other drugs used as long-term treatment for peripheral vascular 
disease. It is well tolerated, and the adverse reactions described after oral administration 
are related mainly to transient gastrointestinal intolerance, ie, nausea, dyspepsia, and minor 
bowel symptoms. Sulodexide may become the treatment of choice when dealing with vascular 
diseases and their complications, as well as for the prevention of venous thromboembolic 
disease, being particularly indicated in elderly patients, due to its good tolerability and ease 
of management.
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Introduction
Peripheral vascular disease includes both arterial (with the exception of cardiac 
and cerebral) and venous pathologies. The most common pathology is chronic 
arteriopathy of the lower limbs, which is a chronic and gradual process normally 
resulting from atherosclerotic injury. It becomes established mainly in the innermost 
layer of the arterial wall and causes arterial thrombosis as a final complication.1 
Venous vascular disease manifests as thrombosis, resulting from the synergis-
tic interaction of endothelial damage, rheologic modification of blood flow, and 
hypercoagulability.2
The pharmaceutical arsenal for prophylaxis and treatment of atherothrombotic 
arterial pathology and venous thromboembolism includes several options, 
ie, hypolipidemic drugs,3 antiplatelet agents 4 drugs with anticoagulant or antithrombotic Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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properties, such as warfarin or acenocoumarol, as well as 
nonfractionated heparin, low molecular weight heparin 
(LMWH),5, 6 and dermatan sulfate. 7
Sulodexide is a highly purified glycosaminoglycan (GAG) 
obtained from porcine digestive mucosa and is composed of 
a mixture of 80% heparan sulfate (an electrophoretically fast 
moving fraction with a low molecular weight of 7000 Da 
and affinity for antithrombin III) and 20% dermatan sulfate 
with a high molecular weight (25,000 Da) and affinity for 
the heparin II cofactor. This composition contributes to its 
antithrombotic and antithrombin action and a lower risk of 
hemorrhage.8– 13 Sulodexide is therefore an ideal drug for the 
prophylaxis and treatment of arterial and venous peripheral 
vascular diseases.
Sulodexide has been marketed in Europe (Spain, Italy, 
and Eastern European countries), South America, and Asia. 
It is currently under development in the US as a treatment 
for diabetic nephropathy. The aim of this report is to sum-
marize the biologic actions of sulodexide in peripheral 
vascular disease, as well as the results of studies evaluat-
ing the efficacy of sulodexide in patients affected by these 
pathologies.
Pharmacokinetics of oral  
sulodexide
Absorption
The pharmacokinetics of sulodexide in humans after 
oral administration of a single 50 mg or 100 mg dose 
in volunteers was evaluated in several studies by using 
radioactive isotopes, ie, C-14,14 I-131,11 I-125,15 and 
deuterium.16,17 After oral administration, sulodexide under-
goes rapid and progressive intestinal absorption, with the 
presence of two peaks in plasma corresponding to both 
components (dermatan sulfate and heparan sulfate) and 
with concentrations of 0.2–1.0 mg/L at 1–10 hours after 
administration.14
After ingestion, sulfated GAGs are absorbed, undergoing 
significant degradation and loss of the sulfate groups, which in 
turn reduce the molecular weight of the drug. The desulfated 
derivates appear in the blood stream up to 3–4 hours after 
oral administration, accompanying the sulfated fractions for 
up to 24 hours, with no relevance from a pharmacodynamic 
point of view.17
Observation of the radioactive fraction linked to the 
unmodified drug indicates that the relative bioavailability 
of oral sulodexide is in the range of 40%–60%. Half-life 
after ingestion of a 50 mg dose is 18.7 ± 4.1 hours, and 
25.8 ± 1.9 hours after a 100 mg dose.11
Distribution
Sulodexide undergoes rapid and progressive   absorption, 
reaches high plasma concentrations, and is widely distrib-
uted, particularly in the monocellular endothelial layer, 
making it very interesting as far as blood clotting is con-
cerned. Reduction in plasma concentration not only depends 
on rapid drug distribution, but also on binding with the 
endothelial cell receptors in both arteries and veins, due to 
the affinity of GAGs for this cellular layer.18– 20 The long half-
life of sulodexide may be due to the progressive liberation 
of products linked to these cells, and explains the long-term 
persistence of the drug in plasma. It is also possible that this 
process is influenced by metabolic degradation, reducing 
its affinity for cell receptors.17 Tissue uptake occurs via 
the extracellular matrix, as well as the renal and hepatic 
parenchyma.21
elimination
Sulodexide is eliminated via the renal, bile, and fecal routes. 
Renal excretion is the main route, accounting for 55.3 ± 2.9% 
of drug excreted over 96 hours.11, 15 A large part of the radio-
activity excreted after 48 hours corresponds to degradation 
products as a result of intracellular biotransformation. Biliary 
excretion accounts for 23.5 ± 2.3% of the dose removed 
within 48 hours, and the remaining amount is eliminated by 
feces, accounting for 23.5 ± 2.8% at 48 hours.14
Pharmacodynamics
Mechanism of action and pharmacologic 
effects
From a pharmacologic point of view, sulodexide is very 
different from nonfractionated heparin due to its prolonged 
half-life and a systemic anticoagulant effect, which is 
less potent and therefore less likely to cause hemorrhage. 
Sulodexide, when administered orally exerts potent lipolytic 
activity,22 as well as activity related to proteoglycan synthesis 
by smooth muscle cells, associated with suppression of 
cell proliferation and inhibition of a significant part of 
atheromatous plaque development.16,23 At the same time, 
sulodexide inhibits migration of smooth muscle cells towards 
the innermost layer, as a result of the drug’s antithrombin 
and anti-platelet aggregation effect.24–26 The marked efficacy 
of sulodexide derives from its dual action of catalyzing the 
inhibition of thrombin by antithrombin III (ATIII) and by 
heparin cofactor II (HCII), with the added advantage of 
not increasing bleeding.27 Sulodexide possesses marked 
systemic fibrinolytic activity due to the liberation of tissue 
plasminogen activator (tPA), with marked functional and Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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antigenic reduction of plasminogen activator inhibitor-1 
(PAI-1),25,28,29 and a reduction in plasma fibrinogen concen-
tration, favoring the reduction of blood viscosity.23
In short, oral administration of sulodexide has very 
effective antithrombotic and antithrombin activity, with 
efficacy and safety demonstrated in a wide range of vascular 
pathologies.27,30
Rheology and sulodexide
The hemorrheologic mechanism is important in both 
peripheral arterial pathology and venous thromboembolic 
disease.31,32 Blood flow in patients can be determined 
by measuring blood and plasma viscosity, which are 
important parameters for measurement of atherosclerosis 
and thrombotic processes.33 Plasma viscosity depends on 
the plasma concentration of fibrinogen, although other 
proteins, such as immunoglobulins and lipoproteins, are 
able to increase viscosity.34 Increased viscosity leads to 
reduced blood flow, an increase in shearing forces, and 
alteration of the endothelial cells. Research on the hyper-
viscosity phenomena in arterial vascular structures and their 
modification by sulodexide is particularly interesting. Many 
studies have found that sulodexide significantly reduces 
viscosity after intramuscular (IM) administration followed 
by long-term oral administration.35–42
Sulodexide administered exclusively via the oral route has 
also been shown to be effective in the treatment of disorders 
involving hyperviscosity. Oral administration of 50–100 mg 
doses results in a marked reduction of plasma viscosity, which 
can be observed as early as 1 week after the start of treat-
ment.23,28,43–45 Some studies have found a significant reduction 
in global blood viscosity,23,28 whereas global viscosity has 
remained unchanged in other studies.45
Lipids and oral sulodexide
Sulodexide was initially used primarily as a hypolipidemic 
drug due to its activity of liberating lipoprotein lipase after 
parenteral or oral administration.46 In a cholesterol-fed rabbit 
model, sulodexide significantly reduced plasma cholesterol 
levels and cholesterol accumulation in the rabbit abdominal 
aorta compared with controls.47 The disappearance of 
radiolabeled low-density lipoprotein (LDL) was enhanced 
after the addition of sulodexide in liver perfusates of healthy, 
lipidemic, or hypertriglyceridemic rats. Sulodexide was 
shown to interact with very low-density lipoprotein (VLDL) 
by reducing lipoprotein uptake in the rabbit aorta and by 
increasing hepatic metabolism in normal and hypertriglyc-
eridemic animals.48
A similar response can be observed in the lipid profile of 
patients with peripheral vascular disease, as well as in those 
with diabetic vascular complications, in whom there is a 
marked reduction in triglycerides, an almost total response 
in the reduction of total cholesterol, and a variable response 
in the increase of high-density lipoprotein (HDL). Less 
significant is the reduction of the LDL fraction. In general, 
sulodexide´s influence on the lipid profile can be seen best 
after parenteral administration, but this is maintained during 
oral administration, even showing a trend towards improving 
the lipid profile further as treatment continues, and the lowest 
lipid concentrations being found at the end of oral treatment. 
Studies performed using only oral dosing demonstrated a 
significant reduction in triglyceride concentrations, with 
cholesterol levels remaining unchanged.22,23,45
The determination of apolipoprotein levels, although less 
frequently studied, allows for the evaluation of situations of 
vascular risk and deterioration, and is an invaluable index for 
the study of atheromatous disease. In patients with peripheral 
vascular disease undergoing treatment with sulodexide (intra-
muscular + oral), an increase in apolipoprotein A-1 (Apo A-1) 
and a reduction in Apo lipoprotein B (Apo B) has been found, 
being particularly marked with oral administration, and more 
significant at the end of treatment.37,49,50 In a study of diabetic 
patients with vascular complications treated with sulodexide, 
an increase in Apo A-1 could be observed with no change 
in Apo B,51 while in another study of a comparable patient 
population, no modifications were observed.52
Hemostasis and sulodexide
Until the 1970s, studies of the complex mechanism of 
hemostasis largely involved analysis of the extrinsic and 
intrinsic phases of blood coagulation, where plasma was the 
substrate. Few references were made to vascular permeability 
or to the vascular wall, the latter being considered to be 
merely a passive, inert hemostatic barrier.53 Since the 1970s, 
the study of hemostasis has focused primarily on the vascular 
wall, more specifically the vascular endothelium, where the 
main functions of hemostasis are centered, as well as the “in 
excess” pathologies of thrombosis and atherosclerosis, which 
are also currently receiving particular attention due to their 
immense socioeconomic importance.54–59
Experimental studies have shown the effectiveness of 
heparan sulfate in both the prevention and treatment of 
venous thrombosis. In an early study, it was observed that 
heparan sulfate could inhibit venous thrombus formation as 
effectively as heparin,60 even at low doses. This is due to the 
fact that heparan sulfate can inhibit thrombus formation via Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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HCII, ie, not only via thrombin adherent to the fibrin of the 
thrombus, but also via free circulating thrombin.61,62
A comparative study of sulodexide and heparin in 
thrombus formation induced in the rabbit jugular vein 
demonstrated the efficacy of sulodexide in acceleration of 
thrombin inhibition by both ATIII and HCII. Sulodexide 
produced lower systemic anticoagulant activity, therefore 
reducing the probability of hemorrhagic complications.13
Sulodexide’s efficacy was also demonstrated in studies 
of thrombosis induced by ligature of the rat inferior vena 
cava.63,64 As in the induced thrombosis studies, a fibrinolytic 
effect was observed in rats and attributed to a reduction of 
plasma PAI-1 and increased tPA.64
Other investigators have assessed the activity of oral 
sulodexide in atherothrombotic disorders. In a pilot study 
of patients with hyperviscosity syndrome, a marked func-
tional and antigenic reduction of PAI was observed, as well 
as an increase in tPA activity, both of which are endothelial 
components of the fibrinolytic system, with no change in 
plasma tPA concentration.28 In a double-blind, placebo-con-
trolled, crossover study in patients with chronic peripheral 
vascular disease or recurrent venous thrombosis,30 a 
marked reduction of PAI activity (P , 0.001) and plasma 
fibrinogen (P , 0.001), as well as an increase in fibrinolytic 
activity (P , 0.01), were observed after oral administration 
of sulodexide 100 mg/day for 30 days. No changes in global 
blood coagulation parameters, thrombin time (TT), partial 
thromboplastin time, or plasminogen concentrations were 
found. These data support the hypothesis that sulodexide 
accumulates in endothelial cells after oral administration. 
The same results were found in other randomized studies 
using 100 or 200 mg sulodexide.25,65
interaction with other drugs
A number of concomitant cardiovascular diseases can affect 
middle-aged to elderly patients with peripheral vascular 
disease, resulting in polypharmacy in many cases. This has 
led to the study of the possible interactions of sulodexide with 
other drugs. No interference was found with the concomitant 
use of sulodexide and diuretics/antihypertensives, oral 
hypoglycemic drugs, gastric protectors, bronchodilators and 
expectorants, tranquilizers and anxiolytics, hepatic protectors, 
antibiotics/systemic disinfectants, nitroderivatives, insulin, 
and LMWH.66–68 To summarize, oral administration of 
sulodexide in cardiovascular disease, metabolic disease, and 
in the prevention and treatment of thromboembolic disease, 
does not interfere with the pharmacologic action of other 
commonly used treatments.
Efficacy in peripheral vascular 
disease
Peripheral arteriopathy
Peripheral, obstructive, chronic arteriopathy is a common 
disorder and is caused by low perfusion pressure causing pain 
at rest and trophic changes in the lower limbs. Pain is intense, 
particularly at night, and leads to psychologic and clinical 
deterioration in many patients. The pharmacologic arsenal 
comprises drugs directed not towards resolving obstructive 
arteriopathy, but towards improving circulation, viscosity, 
and arterial blood flow to relieve pain and trophic changes.
A large number of clinical studies have been performed 
with sulodexide in this setting, some of which were double-
blind,35–39,49,50,69–72 most were placebo-controlled, and some 
followed an open design.41,73–78 All studies included patients 
with Leriche-Fontaine stages I–III disease, ranging from no 
clinical symptoms to intermittent claudication and signifi-
cant symptoms. Depending on the study, patients initially 
received IM sulodexide (generally 60 mg) for 20 days, 
followed by oral administration (60 mg/day) for 40 days to 
6 months.
Treatment with sulodexide significantly improved clinical 
symptoms, as well as objective and functional signs in these 
studies. Improved tissue perfusion at the muscle level was 
indicated by better walking distance on treadmill testing. 
This improvement in muscle perfusion is attributable to 
the reduction of plasma, total blood, and serum viscosity 
(the latter being less marked), and is the main objective of 
treatment with sulodexide. Results using the Winsor Index, 
Doppler, and plethysmography confirm that oral treatment 
is capable of maintaining the benefit achieved after initial 
parenteral sulodexide treatment. The continuation of oral 
sulodexide is important from a biologic perspective, because 
oral administration stabilizes, prolongs, and improves the 
effects achieved by the parenteral route.
In other double-blind, placebo-controlled studies, 
sulodexide was administered only by the oral route to 
patients with Leriche-Fontaine stages I–II peripheral   vascular 
disease 23,45,66 or cerebrovascular disease.22 The doses adminis-
tered varied from 50–100 mg/day for 30–90 days. The Winsor 
Index and treadmill test performance improved significantly 
(both P , 0.001) compared with placebo, probably due to 
improved local perfusion.66
A marked reduction was observed in serum viscosity 
(P , 0.001), fibrinogen levels (P , 0.05),23,45 and in vitro 
platelet aggregation (P , 0.05).22 A similar effect was 
observed on the lipid profile, with a significant reduction in 
triglycerides (P , 0.01), and a significant increase in HDL Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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(P , 0.05).22,23 Decreased concentrations of fibrinogen, 
plasma viscosity, total blood, and platelet aggregability were 
all considered to be responsible for improved blood flow and, 
subsequently, improved clinical symptoms.
In summary, the observed modifications in the Winsor 
Index, improved peripheral blood flow, and decreased 
claudication symptoms indicate that treatment with 
oral sulodexide is effective in eliminating or reducing func-
tional damage and clinical symptoms caused by chronic 
peripheral arteriopathy, when still amenable to medical 
therapy. Similar findings have been reported in diabetic 
patients with peripheral vascular disease.79 Importantly, 
the reduction of plasma fibrinogen by sulodexide has 
been observed not only in clinical studies of parenteral 
and oral dosing, but in studies using only oral sulodexide 
administration.
Arteriosclerosis associated  
with metabolic disorders
This section reviews the studies performed in patients 
with peripheral vascular disease associated with metabolic 
disorders, in particular diabetes and hyperlipidemia. Three 
double-blind, placebo-controlled studies are reviewed.80–82 
The dosage was fairly uniform, with the parenteral phase 
consisting of 30–60 mg/day administered via the IM route for 
10–30 days, followed by 60 mg/day orally for up to 90 days. 
In the first study, the results demonstrated a reduction in 
lipid parameters for both diabetics and nondiabetics, and a 
further progressive reduction during oral administration.80 
The next study was done in patients with peripheral athero-
sclerosis and Leriche-Fontaine Stage II vasculopathy, having 
claudication and other symptoms requiring chronic therapy 
(excluding insulin-dependent diabetes and hyperlipidemia). 
A significant reduction of triglycerides (P , 0.05) and an 
increase in HDL (P , 0.05) was observed in sulodexide-
treated patients compared with placebo. Likewise, peripheral 
circulatory assessment improved significantly on oscillom-
etry (P , 0.01) and plethysmography (P # 0.05).81 Another 
study in patients with generalized atherosclerosis, diabetes, 
and altered lipid metabolism showed a marked reduction 
in triglycerides (P , 0.001) and cholesterol (P , 0.05), 
as well as increased HDL (P , 0.01), with a reduction in 
blood (P , 0.05), plasma (P , 0.01), and serum (P , 0.01) 
viscosity in the sulodexide group, mainly during the oral 
administration period.82
Five open, uncontrolled studies40,83–86 in patients with 
generalized atherosclerosis, cerebral vasculopathy, chronic 
arterial insufficiency, and/or heart disease demonstrated 
similar results. A marked reduction in triglycerides 
(P , 0.001) and cholesterol (P , 0.05) were observed in 
patients with dyslipidemia Type IV, the reduction being less 
marked in those with Type IIb dyslipidemia. In general, sig-
nificant improvement was seen for intermittent claudication 
(P , 0.001) and night pain and cramps (P , 0.001). The 
same effect was observed in patients with heart disease and 
anginal symptoms, in whom no recurrences of symptoms 
were documented. With regard to cerebrovascular symp-
toms, a mid to high percentage of patients demonstrated a 
favorable outcome at the end of oral treatment, being very 
effective in the prevention of recurrent transient ischemic 
attacks.
In summary, in dyslipidemic patients with a profile of 
atherosclerosis affecting different organs, administration 
of sulodexide normalized the relevant atherosclerotic 
parameters and produced favorable clinical outcomes for 
patients.
vascular complications of diabetes
It is well known that diabetes in adults is an important risk 
factor for atherosclerosis, progressing to arteriopathy of the 
lower limbs and often requiring amputation. Prevention of 
thromboembolic complications is therefore essential and 
has led to the study of the efficacy of sulodexide in diabetic 
patients with atherosclerosis.
The clinical and laboratory findings of various 
studies carried out in diabetic patients with vascular 
complications51,52,73,87–90 have been particularly interesting. 
In these studies, sulodexide was administered as 60 mg/day 
intramuscularly for 20 days followed by 60 mg/day orally 
for 70 days. In a double-blind study of diabetic patients 
with Leriche-Fontaine grades II–III peripheral arteriopa-
thy, 51 a reduction in total lipids was observed (P , 0.02) 
at the end of treatment, corresponding to a reduction in 
total cholesterol (P , 0.05) and triglycerides (P , 0.005). 
Additionally, an increase in HDL was achieved (P , 0.03), 
as well as in Apo A (P , 0.02). No changes in Apo B 
or fibrinogen were observed. The change in lipid profile 
correlated with improvement in symptoms of intermittent 
claudication.
In another study of patients with vascular complications,87 
there was a progressive reduction in total cholesterol 
(P , 0.001), an increase in HDL (P , 0.05), and a 
significant reduction of plasma fibrinogen (P , 0.001). 
These findings were again accompanied by improvement 
in vascular symptoms, including those of intermittent 
claudication.Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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Patients with dyslipidemia and severe atherosclerotic  symp-
toms have been investigated,88 and found to show improvement 
in cerebrovascular, coronary, and peripheral arterial symptoms. 
Cholesterol (P , 0.001) and triglycerides (P , 0.05) were 
significantly reduced, which explains the clinical benefit expe-
rienced by the majority of patients.
Treatment with sulodexide was also evaluated in an open, 
randomized study of patients with types 1 and 2 diabetes 
mellitus or impaired glucose intolerance, accompanied by 
arterial vasculopathy of the lower limbs, retinopathy, and 
coronary artery disease.52 Changes in plasma parameters 
were assessed, as well as clinical outcomes. The majority 
of patients (48%) showed clinical and subjective improve-
ment accompanied by a reduction in platelet adhesion 
(P , 0.01) and fibrinogen levels (P , 0.05). Triglyceride, 
total cholesterol, HDL, total lipid, and Apo A and B levels did 
not show any significant reductions. However, the reduction 
of platelet adhesion found at the end of treatment is notewor-
thy, being particularly interesting for the clinical evolution 
of patients with atherosclerosis injuries.
Finally, three open studies73,89,90 including diabetic patients 
with vascular complications were reviewed. A reduction 
in plasma triglycerides (P , 0.05) and total cholesterol 
(P , 0.05) were observed in all patients. A significant reduc-
tion in fibrinogen (P , 0.05) was seen in one of the studies89 
compared with a slight reduction at the end of treatment in 
other study.90 In all groups, improvement in intermittent 
claudication symptoms was observed (P , 0.001,73 
P , 0.05,89 and P , 0.0190) and was seen mainly during 
oral treatment.
Prophylaxis and treatment  
of venous thromboembolic disease
The efficacy of sulodexide in the prevention and treatment 
of venous thromboembolic disease lies in its bioavailability 
after oral administration and in its affinity for endothelial 
and subendothelial cellular elements.18,19 Six studies 
were reviewed in which doses of 50–100 mg/day were 
administered for up to 24 months. Patients with deep vein 
thrombosis (DVT), varicose syndrome, and recurrent throm-
bosis were studied in a double-blind, placebo-controlled 
crossover study.91 During the administration phase, a very 
significant (P , 0.001) PAI antigen reduction was observed 
compared with baseline, and no change on placebo. The 
concentration of fibrinogen in plasma was slowly reduced 
during treatment with sulodexide, and was statistically 
significant at the end of treatment (P , 0.001), again not 
observed with placebo. Fibrinolytic activity studied using 
the fibrin plaque technique also showed a significant increase 
(P , 0.01).
These results are consistent with those of other clinical 
trials,23,30 whereby prophylactic activity was related to a 
significant reduction in plasma fibrinogen (P , 0.05) and 
PAI (P , 0.001), with no change in antithrombin and TT, 
indicating a systemic anticoagulant effect. These results 
justify the use of sulodexide at the recommended doses in 
patients with venous disorders and at risk of thrombotic 
complications.
In a multicenter, randomized, double-blind, double-
masked trial,92 patients with chronic venous insufficiency 
secondary to varicose syndrome or to a thrombotic epi-
sode confirmed by Doppler were allocated to receive 
50–100 mg/day of sulodexide for 60 days. The results 
demonstrate a significant improvement in venous pressure, 
assessed in the saphenous and tibial veins, with significant 
clinical improvement in all groups (P , 0.001) at the end of 
treatment, which can be attributed to the effect of sulodex-
ide on thrombotic factors, ie, tPA, fibrinogen, and plasma 
viscosity, which was more rapid in patients receiving doses 
of 100 mg/day.
The incidence of long-term recurrent thrombosis 
was evaluated in a multicenter study93 of patients with 
confirmed DVT. The patients were treated during the acute 
phase with the normal dosing schedule of heparin plus oral 
anticoagulation for 6 months. At the end of this period the 
patients were randomized to receive sulodexide 50 mg/day 
for 24 months or to a control group without medication. At 
6 and 12 months, the incidence of recurrent venous throm-
bosis was significantly lower in the treated group (P , 0.05). 
At 24 months, the overall incidence of recurrent thrombosis 
was 17.9% in the control group and 7.4% in the treated group 
(P , 0.05). Oral administration of sulodexide prevented 
40%–60% of recurrent thromboses over a 2-year period, 
and confirmed the efficacy of sulodexide as prophylaxis for 
thromboembolic disease.
Sulodexide was also compared with acenocoumarol 
as secondary prophylaxis for DVT in a controlled, open, 
parallel-group pilot study.68 Patients in the sulodexide 
group received 60 mg/day for 3 months and the other 
group received acenocoumarol adjusted according to 
INR. There were no differences in clinical outcome or 
in the number of thrombotic complications. No hemor-
rhagic complications were observed in the sulodexide 
group, whereas 1 major hemorrhage and 9 episodes of 
minor hemorrhage occurred in the acenocoumarol group 
(P = 0.014). These results suggest sulodexide may be Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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used as an alternative to acenocoumarol in this patient 
population.
Prophylaxis of venous thromboembolic complications is 
particularly important in the immobile elderly. A study was 
performed in elderly patients with hemiparesis at high risk of 
thromboembolic complications and suffering from a variety 
of concomitant conditions, including ischemic heart disease 
(7%), diabetes (30%), and dyslipidemia (20%).94 Treatment 
consisted of sulodexide 60 mg intravenously twice daily for 
1 month, followed by 50 mg/day orally for a further month. 
No venous, cerebral, or cardiac thromboembolic episodes 
were detected during the 2 months of treatment, in spite 
of a mean age of 71.6 (61–81) years, with immobility and 
comorbidity.
The efficacy of sulodexide has also been studied in patients 
affected by venous ulcers of the lower limbs. Chronic venous 
stasis produces deterioration of endothelial cells, alteration 
in the microcirculation, including inflammation, and, with 
time, the development of ulcers resistant to treatment. In a 
randomized, placebo-controlled study95 of patients affected by 
venous ulcers of the lower limbs, sulodexide 60 mg/day IM 
was administered for 20 days, followed by 100 mg/day orally 
for 70 days. Patients treated with sulodexide showed complete 
resolution of venous ulcers after both 2 and 3 months of treat-
ment (P = 0.018 and P = 0.004, respectively).
Prophylaxis of trauma-related 
venous thromboembolic disease
In traumatology there is evidence that dermatan sulfate has a 
prophylactic effect, due to the fact that it catalyzes thrombin 
inhibition by HCII.96 Two clinical studies were reviewed to 
assess the efficacy of sulodexide as prophylaxis in patients 
undergoing arthroplasty of the hip or knee. The first was a 
prospective controlled study 97 in which postsurgical treat-
ment was started in hospital with the administration of 
LMWH, followed by sulodexide 60 mg/day for 30 days. Echo 
Doppler was performed on days 15 and 30 of sulodexide treat-
ment. The results showed significant (P , 0.0001) efficacy 
in thromboembolic prevention in patients who completed 
their prescribed course of sulodexide treatment. In another 
open study98 in patients undergoing arthroplasty of the knee, 
thromboembolism prophylaxis was started after discharge 
from hospital. All patients were treated with LMWH dur-
ing their postoperative stay and afterwards received 60 mg/
day sulodexide for 30 days. At the end of the study, 95.8% 
of patients were free of thrombotic complications; only four 
cases were observed, two of which were asymptomatic. In 
summary, sulodexide is capable of significantly reducing 
thromboembolic complications in patients who have 
undergone arthroplasty of the hip, and is an ideal choice for 
outpatient treatment.
Economic considerations
Some research has been performed assessing the cost of 
treatment with sulodexide, mainly in DVT prophylaxis. In 
a previously mentioned study,93 patients with DVT were 
treated with LMWH followed by oral anticoagulation for 6 
months and were subsequently allocated to receive either 
50 mg/day of sulodexide for 2 years or follow-up with no 
other pharmacologic support. The average cost of treating 
one DVT episode was estimated at €23,000, which was 
equivalent to the annual cost of treating 53 patients with 
sulodexide. According to this study, sulodexide prevented 
7–8 recurrent DVT episodes per 100 patients per year. 
The treatment of 53 patients with sulodexide therefore 
prevents 4–5 recurrent thromboses, with corresponding 
cost savings.
In a pilot study of secondary DVT prophylaxis,68 an analysis 
was performed to analyze the costs associated with treatment 
using sulodexide or acenocoumarol. The estimated costs were 
based on the doses used in the clinical trials of sulodexide 
60 mg/day or acenocoumarol 2 g/day and 3 months of treat-
ment. The analysis considered the necessary INR adjustments, 
follow-up visits, and corresponding laboratory tests in accor-
dance with normal clinical practice. It was also assumed that 
neither additional visits nor complementary tests were neces-
sary with sulodexide. The analysis demonstrated a cost-saving 
per patient of 500% with sulodexide compared with acenocou-
marol during the study period (€484 at the time of the analysis). 
The sensitivity analysis was strongly in favor of sulodexide. It 
is important to note that only data on efficacy were analyzed. 
Indirect costs, such as loss of productivity resulting from visits 
associated with acenocoumarol, were not considered.
In both cases, cost-analysis in favor of sulodexide needs 
to be considered in the context of the number of target 
patients treated in a reference hospital or outpatient vascular 
departments, which would provide great savings to the health 
services.
Safety profile
Oral administration of sulodexide is extremely well tolerated, 
to the extent that no adverse events were reported in some of 
the studies reviewed,45,93,99 with a very low incidence in oth-
ers.39,66,67,78,92,95 The adverse effects consist mainly of transient 
gastrointestinal disturbances appearing at the start of treatment, 
and include diarrhea, epigastralgia, dyspepsia, heartburn, Journal of Blood Medicine 2010:1 submit your manuscript | www.dovepress.com
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dizziness, and other minor digestive problems. These events 
were assessed to be of mild to moderate intensity, and generally 
did not require interruption of treatment. Allergic reactions, 
such as skin rash, have also been reported but are very rare.
Of particular interest is a randomized multicenter study100 
in which 2016 post-myocardial infarction patients received 
sulodexide 100 mg daily for 11 months. The adverse events 
recorded were 7 cases of nausea and vomiting, 5 cases of 
epigastralgia, and 4 skin reactions. None of these cases 
required interruption of treatment.
In summary, the adverse effects reported in the clinical 
studies with oral sulodexide largely relate to the gastrointes-
tinal system, are short-lasting, of low incidence, and resulting 
in an excellent safety profile.
Conclusion
Considerable clinical experience has been gained with 
sulodexide since it entered the marketplace. Its pharmacologic 
action on the essential mechanisms causing atherothrombotic 
disease, on lipid metabolism, the blood clotting mechanism at 
the vascular wall level, and blood rheology dynamics positions 
sulodexide as a drug which is effective in the treatment of 
peripheral arterial diseases and their complications, as well 
as in the prevention of venous thromboembolic disease.
Sulodexide is a comparatively safe drug, without the 
well-known hemorrhagic complications associated with some 
other compounds (eg, coumarin derivatives and heparin). The 
adverse effects described after oral administration in the clinical 
trials were short-lasting and consisted mainly of gastrointestinal 
disturbances, their incidence being of low significance.
Oral administration of sulodexide does not demonstrate 
any pharmacologic interactions requiring suspension or 
dosage modification in patients being treated for vascular 
diseases and/or metabolic disorders, or in the prophylaxis 
and treatment of venous thromboembolic disease. Sulodexide 
does not require monitoring for dose adjustment, so is 
particularly suitable for middle-aged to elderly patients.
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